Pedersen E, Hogetveit AC, & Andersen A (1973) Cancer of respiratory organs among workers at a nickel refinery in Norway
97% achieved an end-of-treatment response and 90% achieved SVR12.[32] Sofosbuvir-Based Treatment in Phase 3 Trials : In a pooled analysis of data from phase 3 trials using sofosbuvir-based regimens, investigators compared HCV treatment responses in participants receiving opioid substitution therapy during treatment (n = 194) with participants not receiving opioid substitution therapy (n = 4,549).[27] There were no significant differences in SVR12 rates (94% in those receiving opioid substitution therapy versus 97% for those not receiving opioid substitution therapy).[27] Sofosbuvir-Velpatasvir (SIMPLIFY) : In this single-arm, open-label, phase 4 study, 103 participants with chronic HCV genotype 1, 2, 3, 4, 5, or 6 infection and recent (within 6 months) injection drug use were treated with a 12-week course of sofosbuvir-velpatasvir.[22] During the treatment course, 59% (61 of 103) participants were receiving opioid substitution therapy, and 74% (76 of 103) had used injection drugs in the month prior to starting treatment.[22] A total of 97% (100 of 103) participants completed treatment
High Volume Repair Capacity: Contains enough velour to complete hundreds of repairs, ideal for frequent use
Manage Cookies To provide the best experiences, we use technologies like cookies to store and/or access device information
